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Preclinical development 
of a bispecific TNFα/IL‑23 
neutralising domain antibody 
as a novel oral treatment 
for inflammatory bowel disease
Kevin J. Roberts1,2*, Marion F. Cubitt1,5, Timothy M. Carlton1, Lurdes Rodrigues‑Duarte1,5, 
Luana Maggiore1, Ray Chai1,6, Simon Clare3,7, Katherine Harcourt3, Thomas T. MacDonald4, 
Keith P. Ray1, Anna Vossenkämper4, Michael R. West1 & J. Scott Crowe1,2
Anti‑TNFα and anti‑IL‑23 antibodies are highly effective therapies for Crohn’s disease or ulcerative 
colitis in a proportion of patients. V56B2 is a novel bispecific domain antibody in which a llama‑derived 
IL‑23p19‑specific domain antibody, humanised and engineered for intestinal protease resistance, 
V900, was combined with a previously‑described TNFα‑specific domain antibody, V565. V56B2 
contains a central protease‑labile linker to create a single molecule for oral administration. Incubation 
of V56B2 with trypsin or human faecal supernatant resulted in a complete separation of the V565 and 
V900 monomers without loss of neutralising potency. Following oral administration of V900 and V565 
in mice, high levels of each domain antibody were detected in the faeces, demonstrating stability in 
the intestinal milieu. In  ex vivo cultures of colonic biopsies from IBD patients, treatment with V565 or 
V900 inhibited tissue phosphoprotein levels and with a combination of the two, inhibition was even 
greater. These results support further development of V56B2 as an oral therapy for IBD with improved 
safety and efficacy in a greater proportion of patients as well as greater convenience for patients 
compared with traditional monoclonal antibody therapies.
The inflammatory bowel diseases (IBD), Crohn’s disease (CD) and ulcerative colitis (UC) are chronic diseases 
of the gastrointestinal (GI) tract, typically characterized by periods of clinical relapse and  remission1–3. Current 
therapies aim to induce and maintain remission, while minimising adverse effects. For IBD patients who fail to 
respond to standard anti-inflammatory agents, systemic TNFα-neutralising antibodies are currently the most 
effective  treatment4,5. However, up to a third of patients do not respond to induction anti-TNFα treatment and 
in approximately 40% of patients who initially benefit, efficacy is subsequently lost; in the majority of cases due 
to an anti-drug antibody  response6,7. The mechanisms underlying the development and chronicity of IBD are 
multifactorial, and biologics targeting additional proinflammatory cytokines, and pathways for inflammatory 
cell recruitment, have been developed as alternative therapies for anti-TNFα non-responders6,8,9.
Recently, interleukin-23 (IL-23) has been confirmed as another key mediator of mucosal inflammation in both 
CD and  UC10–14. IL-23 is a hetero-dimeric cytokine within the IL-12 cytokine family, which also includes IL-12, 
IL-23, IL-27 and IL-35, and shares a p40 subunit in common with IL-12. IL-12p40 dimerizes with the IL-23p19 
subunit to form IL-23, or with an IL-12p35 subunit to form IL-1215. IL-23 signals through a heterodimeric IL-23 
receptor complex comprising a unique IL-23 receptor (IL-23R) paired with a common IL-12Rβ1 chain that is 
shared with the IL-12  receptor16. Signalling downstream of IL-23/IL-23R/IL-12Rβ1 complex formation occurs via 
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TYK2/JAK2-mediated STAT3  phosphorylation16 and subsequent transcription of inflammatory proteins including 
IL-1717. Multiple lines of evidence support a role for the IL-23/IL-23R axis in IBD. IL-23 and IL-23R expression are 
increased in inflamed IBD mucosal  tissue18,19 and IL-23 production by macrophages and dendritic cells promotes 
the expression of further proinflammatory cytokines by mucosal T cells and innate lymphoid cells in the IBD  gut20,21. 
Furthermore, the upregulation of mucosal IL-23p19 and IL-23R expression, and the expansion of apoptosis-resistant 
intestinal  TNFR2+IL-23R+ T cells, are associated with resistance to anti-TNFα therapy in CD  patients22, leading to 
the hypothesis that IL-23 antagonists are suitable agents for anti-TNFα-refractory patients. The role of IL-23 in IBD 
has been clinically validated with both p40- and p19-specific systemic monoclonal antibodies that are efficacious 
and safe in both CD and UC patients, including those that previously failed anti-TNFα  therapy12–14,23–25.
In spite of these advances, no current monotherapy is curative in IBD and there is an unmet need for 
new therapeutics with sustained efficacy across a broader patient population. Combination therapies that target 
more than one pathway concurrently may be additive or synergistic in terms of efficacy. The safety and potential 
benefits of combining systemically administered biologic therapies with different therapeutic mechanisms have 
been investigated in a number of case studies and in a single clinical trial in patients with  IBD26–29. Results of these 
studies have shown that in most cases the dual biologic treatments were well tolerated and that efficacy appeared 
promising for some combinations. However, compared with existing monotherapies, the greater immunosup-
pressive effects of combining some systemically administered antibodies may result in unacceptable levels of 
infections and other adverse  effects26, particularly during long-term treatment. An orally-delivered combination 
antibody therapy that targets both TNFα and IL-23 and acts locally in the IBD mucosa should circumvent these 
issues, while providing greater potential for clinical efficacy than either of the monotherapies alone.
Single variable domains of llama heavy chain antibodies (SDAs) retain the potency of conventional anti-
bodies (150 kDa) but have greater intrinsic stability and solubility and are a fraction of the size (12–15 kDa)30. 
SDAs can be engineered for resistance to intestinal  proteases31 and to reduce the potential for immunogenicity 
(humanisation). We have developed SDAs for oral administration that have been optimised further for intestinal 
stability and efficient production in yeast; these we have termed “Vorabodies™”. We have previously reported the 
preclinical and early clinical development of Vorabody™ V565, a novel protease-resistant TNFα-neutralising SDA 
of camelid origin, as a treatment for  IBD32–34. In a recent interventional phase II clinical study in CD patients, 
improvements in key measures of clinical efficacy were observed after 6 weeks of V565 treatment, with no safety 
or tolerability issues ( manuscript in preparation). The results of this study have demonstrated the feasibility 
of delivering a therapeutically effective cytokine-neutralising SDA by oral administration to patients with IBD. 
Here we describe the selection and characterisation of a novel anti-IL-23 p19-specific SDA that has been fully 
optimised for oral administration (Vorabody™ V900) and the creation of a bispecific product that combines V900 
and V565 into a single molecule (Vorabody™ V56B2) with potent TNFα- and IL-23-neutralising activity. The 
strategy chosen for coupling the two Vorabodies includes a tryptic-labile peptide linker which is cleaved in the 
small intestine following oral administration, enabling release of the two monomer arms so that each can bind 
independently to its target cytokine without interference from the other.
Materials and methods
Reagents and antibodies. 12G1 and V900 are unoptimised and protease stability optimised anti-IL-23 
domain antibodies, respectively. V56B2 is an anti-TNFα/anti-IL-23 bispecific (V565-(G4S)2-K-(G4S)2-V900) 
antibody in which the component V565 and V900 domains have been coupled C to N terminally via a trypsin-
sensitive 21mer peptide linker. 12G1 was produced with C-terminal 6xHis and FLAG tags, expressed from E. 
coli and purified using Talon affinity chromatography. The C-terminal tags were not found to affect the potency 
or protease stability of 12G1. The V900 and V56B2 used in the current study were produced from S. cerevisiae 
or Pichia pastoris shake flask cultures and purified using CaptoS ion exchange chromatography. V56B2 was 
also expressed in a 0.75L methanol-induced bioreactor fermentation from a Pichia pastoris  mutS PDI strain 
(Validogen, Graz).  ID2A32 (SDA isotype control) and V565, protease stable domain antibodies directed against 
Clostridium difficile Toxin A (TcdA) and TNFα, respectively, were produced from S. cerevisiae and purified 
using CaptoS ion exchange chromatography. Biotinylated V900 was generated using an EZ-Link™ Sulfo-NHS-
LC-Biotinylation kit (Thermo Scientific, 21435) and the anti-IL-23 activity confirmed by IL-23/IL-23R ELISA. 
Adalimumab and etanercept were clinical grade from AbbVie and Pfizer, respectively. Biotinylated adalimumab 
was a custom preparation from LGC, Fordham, UK.
A custom mouse monoclonal antibody specific to V565 (CharT26), with no binding activity for human IgG or 
V900, was generated at the Wellcome Sanger Institute. Other antibodies and assay reagents were sourced or produced 
commercially from R&D systems; Recombinant Human IL-23R-FC (#1400-IR-050), Biotinylated polyclonal goat anti-
human p40 antibody (BAF219), Recombinant Human IL-12Rβ1 (839-B1-100), Murine IL-23R-Fc (1686-MR-050); 
Recombinant human gp130-Fc (671-GP), Recombinant mouse IL-17 (421-ML-025), monoclonal mouse anti-h-IFN-y 
antibody (MAB2852), Recombinant human MMP3 (513-MP-010) and MMP12 (917-MP-010), from Sino Biologicals; 
Recombinant Human IL-23 (CT012-H08H), Recombinant cynomolgus monkey IL-23R-Fc (90123-C02H), Murine 
IL-23 (CT028-M08H), Recombinant marmoset IL-23 (CT037-C08H), from Sigma; Goat serum (G9023), Recombinant 
Human IL-12 (SRP3073), Extravidin-HRP (E2886), Immobilised trypsin agarose (T4019), from Peprotech; Rabbit 
anti-murine IL-17 biotinylated antibody (500-P265BT), Recombinant human IFN-y (300-02-20), from BioLegend; 
Recombinant mouse IL-2 (575402), Rat anti-murine-IL-17A monoclonal antibody (506906), from Thermo Fisher; 
Recombinant soluble human TNFα (PHC3011), from eBioscience; anti-p40 monoclonal capture antibody (14-7129-
81), from Genscript; Monorab rabbit anti-camelid single-domain monoclonal antibody (A01860), from Dako; Swine 
anti-rabbit–HRP (P0217), Rabbit anti-human IgG-HRP specific for gamma-chains (P0214),from Fusion Antibodies; 
Recombinant cynomolgus monkey IL-23 (Custom preparation), from Invitrogen; Donkey anti-mouse-HRP (SA1-100), 
from BAC Leiden; Rabbit anti-SDA polyclonal antibody (custom preparation).
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V900 inhibition of cellular responses to IL‑23. V900 and 12G1 neutralisation of human IL-23 activity 
were assessed in a cell-based assay by measuring inhibition of IL-17 production from murine splenocytes that 
were co-stimulated with murine IL-2 and human IL-23. Cells were cultured in RPMI-1640 medium (Sigma, 
R0883) supplemented with 10% heat-inactivated foetal bovine serum (Sigma, F7524), 2  mM L-glutamine 
(Sigma, G7513), 100 U/mL penicillin and streptomycin solution (Sigma P0781), and 10 mM HEPES (Fisher, 
BPE299-100). Murine IL-17 in the culture supernatant was measured by ELISA. Details of experimental condi-
tions are given in the Supplementary Methods.
In vitro V56B2 digestion and stability studies. Incubation in immobilised trypsin. A full protocol is 
described in the Supplementary Methods. Briefly, immobilised trypsin agarose was prepared according to the 
supplier’s instructions and all incubations were conducted in trypsin buffer (1 mM Tris–HCl, 20 mM  CaCl2, pH 
8.0). 1 mg/mL V56B2 in a 25% Trypsin agarose suspension was incubated at 37 °C for 1 h. Immediately after 
mixing and at selected timepoints during incubation, samples were removed, centrifuged for 2 min at 500 g 
4 °C and the supernatants frozen until analysis by SDS-PAGE. The 1 h trypsin-treated V56B2 was dialysed into 
1 x PBS containing 0.2 mM PMSF (Sigma 93,482) and analysed by IL-23/IL-23R and biotinylated adalimumab 
competition ELISAs.
Incubation in ex vivo intestinal supernatants. Generation of the mouse small intestinal supernatant (MSIS) and 
human faecal supernatant (HFS) pools used in this study has been described  previously32. Antibody solutions 
were prepared at 250 µg/mL in 1 x PBS, pH 7.4 0.1% BSA, and used in digestion reactions at 20 µg/mL in the 
relevant matrices. As a 0 h time point, one aliquot was immediately mixed 1:1 with stop solution (2% BSA, 5 mM 
EDTA, 2 × SigmaFast protease inhibitor cocktail (Sigma S8820), and 1 mM PMSF (Sigma 93,482)) and frozen 
at − 80 °C. Further aliquots were incubated at 37 °C until the desired time, whereupon an equal volume of stop 
solution was added and reactions were frozen. Samples were analysed by IL-23/IL-23R ELISA or biotinylated 
adalimumab competition ELISA for anti-IL-23 or anti-TNFα activity, respectively. Unknown protein concentra-
tions were determined in Graphpad Prism by interpolation against a standard curve.
ELISA assays. Unless otherwise stated, all antibody standard, test samples and cytokine dilutions were pre-
pared in block buffer (1% BSA in 1 × PBS, pH 7.4). Plates were washed with PBST (1 × PBS, 0.05% Tween 20). For 
ELISA assays which used IL-23, 4% Marvel milk was also added to the block buffer. Detection antibodies were 
added in 1% BSA, 1 × PBS. For the analysis of antibodies in MSIS and HFS, or from mouse faecal or intestinal 
homogenates, 2 × Protease Inhibitor cocktail was also added to the block buffer for all assay steps after plate 
blocking. NaCl (6 mM) was also added to the block buffer for ELISAs for mouse faeces and intestinal samples 
for all steps after plate blocking. For the analysis of trypsin-treated V56B2 0.1 mM PMSF was included in the 
ELISA assay buffer. All ELISA reactions were developed with 100 µL TMB substrate (KPL Microwell Peroxidase 
substrate System, Seracare 50-76-00), stopped with 50 µL 0.5 M  H2SO4 and plates read at 450 nm OD.
Protocols for all ELISAs are given in the Supplementary Methods.
Surface plasmon resonance of V900. An anti-p40 monoclonal antibody was coupled to a Biacore CM5 
sensor chip then loaded with recombinant human IL-23 at 2 μg/mL or 0.5 μg/mL at 10 µL/min for 60 s. This 
allowed binding of V900, to the immobilised IL-23p19 subunit, when applied at 0.02, 0.08, 0.3, 1.25 and 5 nM 
for 300 s on and 300 s off at 30 μL/min.
SDS‑PAGE analyses. Protein samples were loaded into a 10% Bis–Tris NuPAGE gel and electrophoresed in 
SDS-MES buffer alongside a protein molecular weight standard; EZ-Run™ Prestained Rec Protein Ladder (Fisher 
BioReagents) or SuperSignal molecular weight protein ladder (Thermo). For protein concentration determina-
tion, samples of unknown concentration were loaded at multiple dilutions and electrophoresed alongside a V565 
reference standard curve. The gels were imaged in an Imagequant LAS 4000 (Cytiva) using the white transmitted 
light table and analysed using Imagequant TL software to determine unknown protein concentrations from the 
V565 standard curve.
Inflammatory MMPs. Following activation, recombinant human MMP3 and MMP12 were co-incubated for 19 
or 22 h, respectively, with V900 or etanercept using conditions described by Biancheri et al.35. Reaction products 
were analysed by Western blotting as described in the Supplementary Methods.
In vivo assessment of GI stability and distribution in mice. The care and use of all mice were in 
accordance with UK Home Office regulations, UK Animals Scientific Procedures Act 1986, under the project 
licence PPL80/2596. This licence was reviewed and approved by The Wellcome Sanger Institute Animal Welfare 
and Ethical Review Committee. The mice were housed and fed as described  previously32. This study is reported 
in accordance with ARRIVE guidelines. In total, 7 mice were used.
GI transit in mice following oral administration. C57BL/6n healthy female mice were pre-dosed by oral gavage 
with 0.1 mL of a gastro-protective vehicle (0.1 M  NaHCO3 containing 350 mg/mL Marvel milk), then dosed after 
10 min with 0.2 mL 0.1 M  NaHCO3 containing 90 mg/mL Marvel milk plus either a mixture of 146 µg V900 and 
140 µg V565 (4 mice) or, in a separate experiment, a single 245 µg dose of V56B2 (3 mice). The studies were not 
blinded and all animals were included in the final analyses. All faeces were collected between 0–3 and 3–6 h after 
dosing and for the V56B2 study the caeca and colons were also removed at 6 h for extraction of the luminal con-
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tents. Intestinal luminal contents and faecal samples were weighed, homogenised in 8 volumes extraction buffer 
(0.6 M NaCl, 1% BSA, 0.05% Tween 20, 2 × SigmaFast protease inhibitor cocktail, Sigma S8820, in 1xPBS) and 
centrifuged at 13,000 rpm at 10 °C for 20 min. The supernatants were stored at − 80 °C until analysis. Samples 
were analysed by biotinylated adalimumab ELISA (for V565), IL-23/IL-23R ELISA (for V900) or V56B2 bridg-
ing assay. Vorabody levels were determined by interpolation from a plate standard curve and multiplied by the 
extraction dilution factor to give the concentration in neat faeces or luminal contents.
Human IBD tissue ex vivo biopsy studies. Research ethics committee approval (reference 10/H0704/73) 
for studies using human tissue was obtained from the NRES Committee London—City & East. The study was 
also approved by the local Barts and The London School of Medicine and Dentistry QMUL Joint R&D office. All 
aspects of the work described were completed following Good Clinical Practice and Good Clinical Laboratory 
Practice guidelines and were performed in accordance with the relevant guidelines and regulations outlined 
by the approving institutions. All patients took part in the study after giving informed written consent. Biopsy 
tissue was obtained from inflamed colonic mucosa during routine endoscopy of patients with UC who had not 
previously received treatment with anti-TNFα or anti-IL-23 mAbs or ustekinumab. Ex vivo IBD biopsy cultures 
for the analysis of phosphoproteins were run as described by Nurbhai et al.34. UC biopsies were incubated in 
culture medium for 24 h with the addition of the SDAs, either ID2A (unrelated control SDA), V565, V900 or a 
mixture of V565 and V900 at the concentrations shown. Tissue samples collected at the end of the experiment 
were snap-frozen and stored at − 70 °C.
For the analysis of phosphoproteins, tissue samples were thawed, lysed in RIPA Buffer (Sigma-Aldrich, R0278) 
supplemented with phosphatase inhibitor cocktail 2 (Sigma-Aldrich, P5726) and protease inhibitor cocktail 
(Sigma-Aldrich, P8340) and the lysate supernatants diluted to 1 mg/mL protein. Lysates (150 µg lysate proteins) 
were analysed on R&D Systems Proteome Profiler human phosphokinase arrays (ARY003B); a membrane-based 
antibody array technology for the parallel determination of the relative levels of human protein kinase phos-
phorylation. Chemiluminescent signals of the arrays were detected on X-ray films, and the spot intensities were 
measured using ImageJ software. The array signals obtained for the four biopsies in each antibody treatment 
group were used to calculate average intensity values for each of the 45 phosphoproteins. Values were plotted as 
histograms or processed using the conditional formatting option in Excel and colours were applied relative to 
the averaged signal of each phospho-protein in the final array data table. A total phospho-intensity value for each 
treatment group was calculated by summing the average intensity values of all 45 proteins and results included 
at the bottom of the array data table.
Results
Selection and engineering of anti‑IL‑23 Vorabody V900. Llamas were immunised with human IL-23 
and boosted periodically using a hyper-immunisation strategy until the antisera contained high titres of IL-23 
neutralising antibodies. Peripheral blood lymphocytes from each llama were extracted and used to construct a 
phage display library from which SDAs with potent IL-23-neutralising activity were isolated. Phage selections 
were carried out to facilitate enrichment of SDA that bound specifically to the p19 subunit of IL-23. Selected 
SDAs were subsequently screened by ELISA for their ability to disrupt IL-23 binding to IL-23R, but not IL-23 
binding to IL-12Rβ1, or IL-12 binding to IL-12Rβ1. This screen identified five p19-specific SDA sequence fami-
lies with  IC50 values in the range 0.2 to 1.5 nM in the IL-23/IL-23R ELISA that had some initial protease resist-
ance. Clones from these families exhibited between 8 and 51% stability after 1 h incubation in mouse small 
intestinal supernatant (MSIS) and 2.5 to 14.3% stability after 4 h incubation in human faecal supernatant (HFS). 
Clone 12G1 (Fig. 1 and Table 1) was prioritised as the most potent p19-specific inhibitor of IL-23, with some 
intrinsic resistance to human intestinal proteases. However, significant engineering was required to improve the 
protease stability profile to a level suitable for use as an orally delivered IBD  therapeutic32. This was achieved by 
substituting amino acid residues from the sequence of SDA 2E9, a highly protease-stable, high yield, SDA that 
binds to IL-7R36 into the corresponding positions in 12G1 (A23E, A24S, Y37F, A60S, E81Q, D83N, V85L, A90T, 
N96A). Other substitutions improving protease stability (L11Q, R19S, L103I), production in yeast (E1D, R116Q) 
and further humanisation of the 12G1 sequence (M69I, V78L, F79Y) were also introduced. Clones containing 
combinations of these substitutions were tested experimentally in multiple iterations for improvements to stabil-
ity in MSIS and HFS, while retaining the full potency of the parent 12G1 clone. In total, 17 substitutions were 
introduced into the 12G1 sequence (Fig. 1) to generate V900, a fully optimised Vorabody™ of molecular mass 
13.2 kDa, 121 amino acids in length, that was produced in Pichia pastoris.
The IL-23-neutralising activity of V900 was demonstrated using a number of assays. Both 12G1 and V900 
potently neutralised human IL-23 binding to IL-23R by ELISA and inhibited the production of IL-17 from 
murine splenocytes that were co-stimulated with IL-2 and IL-23 (Table 1). These data demonstrated that the 
amino acid substitutions introduced into 12G1 to create V900 did not attenuate the IL-23 neutralising activity. 
The binding kinetics of V900 were also analysed by surface plasmon resonance (Biacore) indicating a  KD of 
32 pM. In species cross-reactivity studies, V900 had no effect on the dose-dependent binding of murine IL-23 to 
its receptor nor did it bind to marmoset IL-23 captured on marmoset IL-23R. By contrast, V900 fully neutralised 
binding of IL-23 from cynomolgus monkey (cIL-23) to its cognate receptor, cIL-23R, (Table 1), identifying the 
cynomolgus monkey as a biologically relevant species for toxicological studies. V900 did not bind to human 
IL-12, which shares the common p40 subunit with IL-23, or to IL-27, a further member of the IL-12 cytokine 
family. V900 also showed no interaction with the unrelated cytokines TNFα and IFNγ, confirming the specificity 
of V900 for IL-23p19 and suggesting any off-target interactions would be extremely unlikely.
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V900 is highly stable in the presence of intestinal proteases. The activities of the major small intes-
tinal proteases, trypsin and chymotrypsin, are conserved across mammalian species, whereas proteases present 
in the large intestine are produced by epithelial cells, lamina propria mononuclear cells and host species-specific 
gut  microflora37. To generate testing conditions that reflect these two environments, 12G1 and the fully opti-
mised V900 were incubated in pooled mouse small intestinal supernatant (MSIS) and pooled human faecal 
supernatant (HFS) and the activity remaining at each sampling timepoint was measured by IL-23/IL-23R ELISA. 
12G1 activity was rapidly degraded in MSIS (22–51% remaining at 1 h) and in HFS (5.6% remaining at 4 h) 
(Table 1). Engineering markedly improved the protease stability of this SDA, with V900 showing 40–51% activ-
ity after 4 h in MSIS and 29% activity after 16 h incubation in HFS.
Levels of inflammatory proteases are elevated in the inflamed mucosa of IBD  patients37. In particular, activated 
matrix metalloproteinases (MMPs), such as MMP3 and MMP12 are abundant in these  tissues38,39. These MMPs 
exhibit proteolytic activity on a broad range of protein substrates, including native IgG, therapeutic monoclonal 
antibodies and biologics that contain a human Fc scaffold, such as the TNFα inhibitor  etanercept35. V900 and 
etanercept were incubated for 19 h or 22 h with recombinant human MMP3 or MMP12, respectively, and the final 
products were analysed by Western blotting. Both MMP3 and MMP12 degraded etanercept (Fig. 2). However, 
neither resulted in degradation of V900 over these time periods (Fig. 2).
Figure 1.  Alignment of the primary amino acid sequences of single domain antibodies 12G1 and V900. 
Asterisks (*) denote the position of substitutions introduced into the 12G1 sequence to generate Vorabody 
V900. FR = Framework, CDR = Complementarity determining regions according to KABAT notation.
Table 1.  Activity and protease stability of 12G1 and V900. The activity of each SDA was measured in 
functional receptor/ligand inhibition ELISAs and a primary cell assay using mouse splenocytes. Potency (IC50) 
and affinity values shown are in nM. Protease stability was measured by incubating SDAs in pooled mouse 
small intestinal (2 biological replicates) or human faecal supernatants for relevant time periods and detecting 
residual activity in the human IL-23/23R functional ELISA. Stability values are %, brackets indicate incubation 
time in hours. NT = not tested.
Assay 12G1 V900
Human IL-23/IL-23R ELISA 0.2 nM 0.2 nM
Cynomolgus monkey IL-23/IL-23R ELISA NT 0.7 nM
Cellular potency in mouse splenocytes 9.3 nM 10.7 nM
KD NT 0.032 nM
Mouse small intestinal stability 1 51% (1 h) 51% (4 h)
Mouse small intestinal stability 2 22% (1 h) 40% (4 h)
Human faecal stability 5.6% (4 h) 29% (16 h)
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V900 successfully transits the mouse GI tract following oral dosing. The  in vivo stability of V900 
during gastrointestinal transit was assessed in mice by oral gavage of V900 together with V565, which had previ-
ously demonstrated high stability in the same model as well as in human  studies32. The V900/V565 mixture was 
applied in a vehicle containing sodium bicarbonate and milk protein to protect against low pH and degradation 
in the stomach. Faeces were collected hourly up to either 3 or 6 h and pooled for analysis of TNFα- and IL-23 
binding activities by ELISA at these timepoints. Transit of both V565 and V900 through the mouse GI tract was 
rapid and by 3 h both Vorabodies were detected in the faeces of three out of four mice (Fig. 3). By 6 h, compa-
rable, micromolar concentrations of V565 and V900 were recovered in the stool of all mice, demonstrating the 
high protease stability of both Vorabodies.
Formatting of V565 and V900 into the bispecific Vorabody V56B2. The potency, specificity, pro-
tease stability and excellent production characteristics of V900 made this SDA a strong candidate for combina-
tion with the potent anti-TNFα Vorabody™ V565 (Supplementary Table) to create a single bispecific molecule 
with dual TNFα- and IL-23-neutralising activities.
The molecular design chosen for this bispecific joined V565 and V900 via a flexible, non-immunogenic  (G4S)4 
linker with a central lysine (K) residue to create a deliberate trypsin-cleavage site; (V565-(G4S)2-K-(G4S)2-V900). 
The resulting molecule, V56B2, was expressed from Pichia pastoris with yields of 3.2 g/L obtained in a pilot 0.75 
Figure 2.  Resistance of V900 to degradation by matrix metalloproteases. V900 and etanercept were incubated 
with recombinant human matrix metalloproteinases (MMPs) 3 and 12 for 19 or 22 h, respectively. Pre- and 
post-digestion samples were analysed by Western blotting alongside buffer only (no enzyme) controls. V900 
was detected using a polyclonal rabbit α-SDA primary and an HRP-conjugated polyclonal swine anti-rabbit 
secondary antibody. Etanercept was detected using peroxidase conjugated anti-human IgG specific for Gamma-
chains. Due to the high sensitivity of etanercept to MMPs, some degradation was observed in the time zero 
samples. Blots were visualised using an ImageQuant LAS4000 (Cytiva) on the Chemiluminescensce setting 
for 1 s (etanercept) or 30 s (V900). L = SuperSignal Prestained ladder. MW = Molecular weight in kDa (vertical 
numbers). Full length blots are shown in Supplementary Fig. S4.
Figure 3.  Distribution of V565 and V900 in the faeces of mice following oral administration. Four naïve mice 
were each administered a mixture of 146 µg V900 and 140 µg V565. Faeces were collected between 0–3 and 
3–6 h and V565 and V900 levels in faecal extracts were measured by biotinylated adalimumab competition 
ELISA and IL-23/IL-23R ELISA, respectively. Concentrations shown  are those calculated in the undiluted 
faeces. Error bars =  +/− SD.
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L methanol-fed fermentation, and purification direct from the fermentation supernatant by one-step CaptoS 
ion exchange chromatography.
V565 and V900 monomers are released rapidly from V56B2 on exposure to trypsin and intesti‑
nal fluids. Full-length V56B2 was shown to bind to both TNFα and IL-23 simultaneously by ELISA (Supple-
mentary Fig. S1). Dual binding of both cytokines was demonstrated, irrespective of the order of cytokine bind-
ing. Incorporation of the trypsin-cleavable linker site in V56B2 will result in monomer separation on exposure 
Figure 4.  The V56B2 central lysine linker is cleaved by trypsin and in intestinal supernatants. V56B2 was 
incubated at 37 °C with immobilised trypsin (A), 1/1,000 diluted mouse small intestinal supernatant (MSIS) (B) 
or human faecal supernatant (HFS) (C). Samples were taken for SDS-PAGE analysis at selected time intervals, 
shown in minutes (horizontal numbers). Equal volumes were loaded per lane. ‘St’ is undigested V56B2 standard. 
L = protein standard EZ-Run Prestained Ladder. MW = Molecular weight in kDa (vertical numbers).
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to tryptic proteases of the small or large intestine, releasing V565 and V900 for independent binding to their 
cytokine targets. Rapid separation of the V565 and V900 monomer arms of V56B2 was observed upon incuba-
tion with immobilised trypsin at 37 °C (Fig. 4).
Release of the monomer arms was also demonstrated in 1,000-fold diluted MSIS and HFS (Fig. 4B, C). The 
supernatants were diluted to this extent to allow clear visualisation of V56B2 and the released monomer arms 
by SDS-PAGE, without interference from supernatant proteins.
Figure 5.  V56B2 retains full anti-TNFα and anti-IL-23 activity. (A) V56B2 and the trypsin-liberated V565 
monomer arm were tested alongside the V565 parent in the biotinylated adalimumab competition ELISA. 
Biotinylated adalimumab in the absence of Vorabody was added as a control (B) V56B2 and the trypsin-
liberated V900 monomer arm were also tested alongside the V900 parent in the IL-23/IL-23R ELISA. IL-23 in 
the absence of Vorabody was added as an assay control. Error bars =  +/− SD. N = 3.
Figure 6.  The cleavage products of V56B2 are highly resistant to human faecal proteases. V56B2 and the 
parent monomers V565 and V900 were incubated in pooled human faecal supernatant for 4 h. This timepoint 
was selected for accurate observation of differences in stability. Time 0 and 4 h samples were compared for 
anti-TNFα activity in the biotinylated adalimumab assay (V565 and V56B2) or anti-IL-23 activity in the IL-23/
IL-23R ELISA (V900 and V56B2). The remaining activity in each sample at 4 h was calculated as a survival 
percentage against the 0 h time point. Error bars +/− SD. N = 3.
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Cleaved V565 and V900 monomers retain full potency. The liberated V565 and V900 arms from 
V56B2 were fully resistant to 7.5 units/mL trypsin and demonstrated equivalent activity, compared with the 
parent V565 and V900 monomers and the untreated, V56B2 parental molecule, after 1 h of trypsin treatment 
(Fig. 5). In the case of the V900 arm, a marginal increase in potency was observed for the full-length and trypsin-
cleaved V56B2 preparation, when compared with the parent V900 monomer (Fig. 5B).
The liberated arms of V56B2 also retained the stability attributes of V565 and V900 in the neat, pooled human 
faecal supernatant (Fig. 6), confirming the utility of the molecule for oral delivery and release in the intestinal 
tract.
In vivo cleavage and stability of V56B2 following oral administration in mice. To demonstrate 
the separation of the monomer arms in vivo, 3 mice were dosed with 245 µg V56B2 by oral gavage in the same 
vehicle described above and faeces were analysed using a bridging ELISA that detects the presence of the full 
length bihead. Full length V56B2 was detected by ELISA in the gavage solution, but was absent in the faeces 
even though both monomers were present, demonstrating that the monomer arms were fully liberated from one 
another during transit through the mouse.
V565 and V900 inhibit endogenous protein phosphorylation in human IBD tissue. We have 
previously demonstrated that the TNFα neutralising activity of V565 suppressed the phosphorylation of tyros-
ine kinase receptors and signalling proteins that are increased in inflamed intestinal tissue samples taken from 
patients with a diagnosis of  IBD32,34. A new study was conducted to investigate the effects of combining V565 
with the IL-23-neutralising V900 on the levels of phosphoprotein biomarkers in ex vivo cultures of inflamed UC 
colonic mucosal tissue. To assess the potential for additivity, the antibodies were tested at concentrations that 
had previously shown close to maximal inhibitory activity in the UC biopsy model (V565  75nM32) or in mouse 
splenocyte cultures (V900 150  nM, inhibition of IL-23 induced IL-17 production, Supplementary Fig.  S2), 
respectively.
Following 24 h incubation of colonic biopsies with antibodies ID2A (isotype control), V565, V900 or a mix-
ture of V565 and V900, the phosphorylation levels of a set of tissue proteins were analysed on antibody arrays and 
average signal intensity values (n = 4 patient biopsies/treatment) calculated for all the 45 phosphoproteins. These 
results are presented as histograms (Supplementary Fig. S3) or as a heatmap in Fig. 7. The inhibitory effects of the 
different antibody treatments are demonstrated by a shift from predominantly higher levels of phosphorylation 
(red–orange) for biopsies treated with the control ID2A, to relatively lower phospho-intensity values (yellow to 
green) for biopsies treated with the anti-TNFα or anti-IL-23 antibodies or a combination of the two. These results 
show that when compared with the ID2A control samples, both V565 and V900 each inhibited phosphoprotein 
levels in the UC biopsy cultures, and that the patterns of inhibition of individual target phosphoproteins on the 
arrays were broadly similar. Biopsies treated with the combination of antibodies showed greater reductions in 
the phosphorylation levels of individual analytes relative to those achieved following treatments with the single 
antibodies V565 or V900, and this trend was reflected in the lower total biopsy phosphorylation levels (∑n=45 
phosphoproteins).
The combined antibody treatment inhibited phosphorylation levels of a number of proteins on the array 
by > 50% when compared with the corresponding ID2A treated controls. Of these Lck, Lyn, Fgr, Stat3 and PDGFR 
are known to have functions involved in the regulation of cells that contribute to inflammation and pathology in 
IBD, while others have roles in the regulation of endothelial and epithelial cells (eNOS, b-catenin) or have signal-
ling roles in many cell types (Erk 1/2, Akt, AMPKa, p70 S6K, p53, RSK-1). Decreased phosphorylation of these 
proteins is indicative of decreased cell activation and is consistent with the neutralisation of the endogenously 
produced proinflammatory cytokines TNFα and IL-23 by V565 and V900.
Discussion
Systemically administered anti-TNFα antibodies are currently the most effective treatment for patients with 
moderate-to-severe  IBD4,5. However, a significant number of patients are either refractory to anti-TNFα treat-
ment or lose response over  time6,7, leading to the requirement for additional therapies. Clinical validation for 
the role of IL-23 in IBD has emerged from evaluation of IL-23 neutralising antibodies in patients with CD and 
 UC40. Ustekinumab, a monoclonal antibody that inhibits both IL-12 and IL-23 by binding to the common p40 
subunit, has been approved for the treatment of moderate to severe, active CD and  UC24,41. IL-23, rather than 
IL-12, was subsequently shown to be a key cytokine mediating the development of  IBD42, and further antibody 
development has focused on targeting the IL-23p19 subunit. Recently, several IL-23 p19-specific monoclonal 
antibodies, including brazikumab, risankizumab, guselkumab and mirikizumab have shown efficacy and safety in 
patients with CD or  UC12–14,25. Importantly, IL-23 inhibition was effective in both anti-TNFα naïve and anti-TNFα 
refractory CD  patients12,13. These data strongly suggest that therapies combining TNFα- and IL-23-neutralising 
antibodies could achieve improvements in efficacy and/or duration of response in a wider population than either 
monotherapy alone. This possibility is being investigated in a clinical study to assess the safety and efficacy of 
combining systemically administered anti-TNFα and anti-IL-23 monoclonal antibodies in patients with UC 
which is ongoing (NCT03662542).
Administration of anti-TNFα or anti-IL-23 therapies by infusion or subcutaneous injection is inconvenient, 
can be uncomfortable, and may lead to injection site reactions. Furthermore, a therapy that combines two potent 
immunosuppressive monoclonal antibodies that are administered parenterally risks increased systemic side 
effects and may also be limited by the cost of administering two independently manufactured antibody therapies, 
even accounting for the potential of wider availability of anti-TNFα  biosimilars43 in the future.
10
Vol:.(1234567890)
Scientific Reports |        (2021) 11:19422  | https://doi.org/10.1038/s41598-021-97236-0
www.nature.com/scientificreports/
Figure 7.  Phospho-array data from four UC patient biopsies grouped according to treatment. Biopsies from 
four different UC patients were incubated for 24 h with the different single domain antibody treatments 
(Control (ID-2A) 225 nM; anti-TNFα (V565) 75 nM; anti-IL-23 (V900) 150 nM or V565 75 nM + V900 
150 nM combined). Lysates were analysed on R&D proteome profiler human phosphokinase arrays with 
chemiluminescent detection, image capture on film and quantitation of spot intensities using array analysis 
software. The array phospho-intensity data were averaged for each treatment (n = 4 biopsies). Values were 
processed using the conditional formatting option in Excel and colours were applied relative to the averaged 
signal of each phospho-protein in the final array data set. Red represents proteins with the strongest 
phosphorylation signals; Green represents proteins with the weakest phosphorylation. The inhibitory effects of 
the different antibody treatments are demonstrated by a shift from predominantly high levels of phosphorylation 
(red–orange) for biopsies treated with the isotype control ID2A, to relatively low (yellow to green) phospho-
intensity values for biopsies treated with the anti-TNFα or anti-IL-23 antibodies or a combination of the two. 
For each treatment total phosphorylation values were calculated by summing the averaged (n = 4 biopsies) spot 
intensities of all 45 analytes.
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To address these unmet needs, we have developed Vorabody™ V56B2, the first anti-TNFα/anti-IL-23 dual 
specificity domain antibody for the treatment of IBD. V56B2 combines the benefits of simultaneous inhibition 
of two key IBD pathways in a single molecule with the convenience and safety of oral drug delivery for local 
disease-modifying activity and minimal systemic exposure. Production and purification of V56B2 from Pichia 
pastoris is simple, scalable to commercial levels, cost-effective and free of the viral screening requirements associ-
ated with mammalian cell-based production systems.
The anti-TNFα arm of V56B2, Vorabody monomer V565, is an SDA that potently neutralises both soluble 
and membrane forms of human TNFα; V565 is safe in man and has demonstrated efficacy following oral dosing 
in both UC and CD  patients32,34 (manuscript in preparation). The anti-IL-23 arm of V56B2, Vorabody V900, is 
also an SDA and is described here for the first time. V900 potently neutralises the binding of IL-23 to IL-23R 
and is specific to the p19 subunit of IL-23 with an affinity in the low picomolar range, similar to that described 
for bivalent anti-p19 monoclonal antibodies that have demonstrated clinical efficacy in  IBD44,45.
To neutralise cytokines present in the lamina propria (LP) of the inflamed IBD gut, oral therapeutic antibodies 
must resist degradation by proteases of the intestinal tract and within the inflamed mucosa. In previous studies 
with V565, stability in ex vivo intestinal supernatants and survival during transit through the mouse intestinal 
tract was highly predictive of the ability to deliver micromolar V565 concentrations to all regions of the intestinal 
lumen in humans and non-human  primates33,34. Here, V900 demonstrated excellent survival in ex vivo mouse 
small intestinal and human faecal supernatants, comparable with survival levels reported for  V56532, over time 
periods that are highly relevant for small and large intestinal transit in man (4 and 16 h, respectively)46,47. Moreo-
ver, both V565 and V900 were recovered at similar levels in the faeces of mice dosed orally with an equal mixture 
of the two Vorabodies™ and the favourable protease stability profiles of the monomer arms were fully preserved 
when formatted into the V56B2 bispecific molecule. Both V565 and V900 are also resistant to matrix metallo-
proteases MMP3 and MMP12, which can act to cleave therapeutic mAbs and biologics that contain a human Fc 
 region32,35. Anti-IL-23p19 SDAs have been described previously that are suitable for systemic  administration48. 
However, V900 is the first p19-specific SDA, and V56B2 is the first anti-TNFα/IL-23 bispecific, suitable for oral 
delivery for the treatment of IBD.
For oral delivery in man, V56B2 will be formulated into gastro-protective enteric-coated minitablets, similar 
to those used previously to deliver high (micromolar) concentrations of V565 to the mid-small intestine and 
distal intestine in IBD  patients34. Upon dissolution of the minitablets in the small intestine, the released V56B2 
will be exposed to trypsin which will cleave the central lysine linker, releasing the two monomer arms to bind 
their respective cytokines independently. Release of V565 and V900 from V56B2 was confirmed here in diluted 
mouse small intestinal and human faecal supernatants. Accounting for the dilution factor of the supernatant 
(1,000-fold), separation of the monomer arms from V56B2 would be expected to occur rapidly on release of 
V56B2 from the minitablets after the enteric coat dissolves, which occurs mainly in the small intestine with 
some late dissolution in the large  intestine34. Separation of the monomer arms following oral dosing was also 
confirmed here in the mouse intestinal transit model.
To test the hypothesis that dual inhibition of TNFα and IL-23 may result in greater efficacy in IBD, ex vivo UC 
biopsies were incubated with either V565 or V900, a combination of the two, or an isotype control SDA. There 
were clear reductions in the phosphorylation of a panel of signalling proteins following treatment with V565 and 
V900, alone and in combination, consistent with the neutralisation of TNFα and IL-23 in the biopsies. In support 
of the dual therapeutic approach, signalling proteins involved in inflammation and pathology in IBD showed the 
greatest reduction in phosphorylation with the combination treatment. Despite differences in the signalling of 
TNFα and IL-23 in IBD, the complexity of the current model and the short treatment period make differentiation 
of V565 and V900 activity difficult, and the results of the biopsy studies are best interpreted in terms of overall 
 trends34,49. For example, IL-23 signalling is mediated, via JAK2, by activated, phosphorylated,  STAT316. STAT3 
phosphorylation was reduced here by V900 treatment, as expected. However, STAT3 phosphorylation is also 
upregulated by additional, TNFα-dependent, cytokines including IL-650, which was previously inhibited by V565 
in patient  biopsies32. Indeed, STAT3 phosphorylation was also reduced here by V565 alone. Furthermore, the 
expression of TNFα was reduced in the ileal and colonic biopsies of CD patients administered intravenously with 
the anti-IL-23p19 mAb  risankizumab51. V900 may therefore reduce TNFα-dependent signalling in the current 
biopsies, independently of V565. Given the complexity of these interactions, it is unsurprising that the greatest 
reduction in STAT3 phosphorylation was observed in the combination treatment. An important limitation of this 
ex vivo biopsy culture model is that it does not allow assessment of effects of the antibodies on tissue retention 
of inflammatory cells or dynamic changes in cell migration thought to be important in inflamed tissue in vivo. 
Moreover, since the established proinflammatory phenotypes of some important target cells (eg macrophages and 
T cells) may not be reversible over the 24 h incubation period of the experiment, a longer treatment period may 
be needed to achieve the full effects of combining V565 and V900. This may be particularly relevant for V900, 
which may exert an effect on the IL-23-dependent expansion and maintenance of IL-17-producing T-helper Th17 
 cells42. Due to the small number of patient biopsies investigated in this study it was not possible to demonstrate 
that the differences in phosphorylation levels between V565, V900 or the combination and the control group 
were statistically significant using a Wilcoxon sign rank test. Nonetheless the patterns of inhibition provided 
experimental demonstration of the activity of both TNFα and IL-23 neutralising Vorabodies™ in ex vivo disease 
tissue and is encouraging for the potential efficacy of a bispecific in patients with either TNFα-dependent or 
TNFα-independent disease.
To achieve simultaneous neutralisation of TNFα and IL-23, the released Vorabody arms of V56B2 must transit 
from the gut lumen to the lamina propria (LP). Oral dosing of V565 was previously shown to result in reductions 
in the phosphorylation of protein biomarkers and target engagement with membrane-bound TNFα on cells in 
the LP of UC  patients34. Penetration of V565 present in the gut lumen through the disrupted gut lining was also 
demonstrated in CD patients where V565 was temporarily observed in the serum of the majority of individuals, 
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before being rapidly excreted in the urine (manuscript in preparation). Given the similarities in size of V900 
and V565, it is expected that that the trypsin liberated arms of V56B2 will exhibit the same ability to penetrate 
into the LP, with short-lived systemic exposure. Taken together, the evidence presented here are encouraging 
towards the desired pharmacokinetic profile for V56B2 as a single product that will deliver saturating, therapeutic 
concentrations of both V565 and V900 to the inflamed mucosa in IBD patients, for neutralisation of TNFα and 
IL-23, but without systemic immunosuppression. Given the extensive sequence similarities between camelid 
SDAs and human variable heavy chain  sequences52, the further humanisation of V56B2, the tolerogenic oral 
route of delivery and the short serum half-life of Vorabodies (50 min for  V56533), immune responses against the 
separated arms of V56B2 are expected to be minimal, limiting the potential for the secondary loss of response 
seen with therapeutic mAbs due to development of neutralising anti-drug antibodies (nADAs). Indeed, nADA 
titres close to baseline were observed after 6 weeks dosing of CD patients with V565 (manuscript in preparation). 
These nADAs had no detrimental effect on the clinical safety or efficacy of V565 in man and were primarily IgG 
class antibodies.
Biologic therapies aiming to treat IBD via the oral route have been reported at various stages of 
 development53–58. However, V56B2 is unique in that it is the first orally delivered intestinal protease resistant 
bispecific antibody to provide dual inhibition of two key, clinically validated, IBD pathways without systemic 
immunosuppression. It has the potential to provide greater clinical efficacy for a longer duration in a larger 
proportion of IBD patients than biologics targeting single cytokines.
Data availability
All data generated or analysed during this study are included in this published article (and its Supplementary 
Information files). 
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